Genomics company Pacific Biosciences of California (NASDAQ: PACB) will be announcing earnings results this Thursday afternoon. Here’s what to expect.
PacBio beat analysts’ revenue expectations by 5.2% last quarter, reporting revenues of $37.15 million, down 4.3% year on year. It was a stunning quarter for the company, with a solid beat of analysts’ EPS estimates.
Is PacBio a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting PacBio’s revenue to grow 2.6% year on year to $36.96 million, a reversal from the 24.3% decrease it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.17 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. PacBio has missed Wall Street’s revenue estimates four times over the last two years.
Looking at PacBio’s peers in the life sciences tools & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Illumina’s revenues decreased 3% year on year, beating analysts’ expectations by 1%, and West Pharmaceutical Services reported revenues up 9.2%, topping estimates by 5.6%. Illumina traded down 8% following the results while West Pharmaceutical Services was up 15.9%.
Read our full analysis of Illumina’s results here and West Pharmaceutical Services’s results here.
Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the life sciences tools & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.1% on average over the last month. PacBio is down 4.1% during the same time and is heading into earnings with an average analyst price target of $2.06 (compared to the current share price of $1.41).
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
